Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-08-30
2010-11-02
Chu, Yong (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S317000, C514S462000, C514S254020, C514S422000, C544S367000, C546S192000, C546S209000, C548S240000, C548S518000
Reexamination Certificate
active
07825147
ABSTRACT:
The present invention relates to isoxazoline derivatives, which can be used as selective inhibitors of phosphodiesterase (PDE) type IV. In particular, compounds disclosed herein can be useful in the treatment of AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases in a patient, particularly in humans. The present invention also relates to processes for the preparation of disclosed compounds, as well as pharmaceutical compositions thereof, and their use as phosphodiesterase (PDE) type IV inhibitors.
REFERENCES:
patent: 3312590 (1967-04-01), Elks et al.
patent: 3436389 (1969-04-01), Nathansohn et al.
patent: 3506694 (1970-04-01), Oxley et al.
patent: 3639434 (1972-02-01), Oxley et al
patent: 3642896 (1972-02-01), Collin et al.
patent: 3644353 (1972-02-01), Lunts et al.
patent: 3652554 (1972-03-01), Anner et al.
patent: 3700681 (1972-10-01), Barth
patent: 3705233 (1972-12-01), Lunts et al.
patent: 3721687 (1973-03-01), Elks et al.
patent: 3780177 (1973-12-01), Ercoli et al.
patent: 3928326 (1975-12-01), Brattsand et al.
patent: 3929768 (1975-12-01), Brattsand et al.
patent: 3937838 (1976-02-01), Wetterlin et al.
patent: 3947478 (1976-03-01), Woods et al.
patent: 3980778 (1976-09-01), Ayer et al.
patent: 3983233 (1976-09-01), Brattsand et al.
patent: 3992534 (1976-11-01), Brattsand et al.
patent: 3994974 (1976-11-01), Murakami et al.
patent: 4011258 (1977-03-01), Wetterlin et al.
patent: 4014909 (1977-03-01), Torossian et al.
patent: 4076708 (1978-02-01), Green et al.
patent: 4081541 (1978-03-01), Bertelli
patent: 4098803 (1978-07-01), Torossian et al.
patent: 4115589 (1978-09-01), Lednicer
patent: 4124707 (1978-11-01), Green et al.
patent: 4158055 (1979-06-01), Sultz et al.
patent: 4226862 (1980-10-01), Riva et al.
patent: 4242334 (1980-12-01), Stache et al.
patent: 4290962 (1981-09-01), Tachi et al.
patent: 4298604 (1981-11-01), Hammell
patent: 4335121 (1982-06-01), Phillipps et al.
patent: 4419364 (1983-12-01), Olsson et al.
patent: 4472392 (1984-09-01), Anderson et al.
patent: 4472393 (1984-09-01), Shapiro
patent: 4579985 (1986-04-01), Minderhoud et al.
patent: 4587236 (1986-05-01), Annen et al.
patent: 4619921 (1986-10-01), Kalvoda et al.
patent: 4780469 (1988-10-01), Toda et al.
patent: 4826868 (1989-05-01), Wachter et al.
patent: 4859692 (1989-08-01), Bernstein et al.
patent: 4873259 (1989-10-01), Summer, Jr. et al.
patent: 4992474 (1991-02-01), Skidmore et al.
patent: 5015746 (1991-05-01), Mizushima et al.
patent: 5126375 (1992-06-01), Skidmore et al.
patent: 5243076 (1993-09-01), Skidmore et al.
patent: 5278156 (1994-01-01), Mizushima et al.
patent: 5482934 (1996-01-01), Calatayud et al.
patent: 5565473 (1996-10-01), Belley et al.
patent: 5583152 (1996-12-01), Bernstein et al.
patent: 5686434 (1997-11-01), Kleinman
patent: 5710170 (1998-01-01), Guay et al.
patent: 5712298 (1998-01-01), Amschler
patent: 5837699 (1998-11-01), Sequeira et al.
patent: 5869511 (1999-02-01), Cohan et al.
patent: 5889015 (1999-03-01), Sequeira et al.
patent: 5976573 (1999-11-01), Kim
patent: 6057307 (2000-05-01), Sequeira et al.
patent: 6114367 (2000-09-01), Cohan et al.
patent: 6127353 (2000-10-01), Yuen et al.
patent: 6180781 (2001-01-01), Yuen et al.
patent: 6337324 (2002-01-01), Harmenberg et al.
patent: 6723713 (2004-04-01), Sequeira et al.
patent: 7183321 (2007-02-01), Li et al.
patent: 0 387 941 (1990-09-01), None
patent: 0 515 684 (1992-12-01), None
patent: 0 542 355 (1993-05-01), None
patent: 0 542 356 (1993-05-01), None
patent: 0 419 049 (1995-12-01), None
patent: 0 988 292 (2003-02-01), None
patent: 211/DEL/2005 (2005-02-01), None
patent: 1098/DEL/2005 (2005-05-01), None
patent: 11-071319 (1999-03-01), None
patent: WO 95/14680 (1995-06-01), None
patent: WO 95/14681 (1995-06-01), None
patent: WO 95/24398 (1995-09-01), None
patent: WO 01/90106 (2001-11-01), None
patent: WO 02/26723 (2002-04-01), None
patent: WO 02/32898 (2002-04-01), None
patent: WO 02/50070 (2002-06-01), None
patent: WO 02/081447 (2002-10-01), None
patent: WO 02/100332 (2002-12-01), None
patent: WO 2005/021515 (2005-03-01), None
patent: WO 2006/085212 (2006-08-01), None
patent: WO 2007/045979 (2007-04-01), None
patent: WO 2007/045980 (2007-04-01), None
Fihi et al. Abstract of Bulletin des Societes chimiques Beiges (1995), 104(1), p55-62 (STN serach report).
Co-pending U.S. Appl. No. 11/390,491, Mar. 2006, Palle, et al.
Cited ref-STN-search-10930569.
Vippagunta et al., Advanced Drug Delivery Reviews, vol. 48, p. 3-26 (p. 3), 2001.
Sutherland and Roll, “The Relation of Adenosine-3′,5′-Phosphate and Phosphorylase to the Actions of Catecholamines and Other Hormones”,Pharmacological Reviews, 12:265-299 (1960).
Beavo and Reifsnyder, “Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors”,Trends in Pharmacological Sciences, 11:150-155 (1990).
Nicholson et al., “Differential modulation of tissue function and theraputic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes”,Trends in Pharmacological Sciences, 12:19-27 (1991).
Verghese et al, “Anti-Neutrophil Activity of Cyclic Nucleotide Phosphodiesterase Inhibitors with Varying Cardiotonic Potencies”,Journal of Molecular Cell Cardiology, 12(suppl. II):S61 (1989).
Ashton et al., “Selective Type IV Phosphodiesterase Inhibitors as Antiasthmatic Agents. The Syntheses and Biological Activities of 3-(Cyclopentyloxy)-4-methoxybenzamides and Analogues”,Journal of Medicinal Chemistry, 37:1696-1703 (1994).
DiSanto and Heaslip, “Identification and Stabilization of Large Molecular Weight PDE-IV from U937 Cells”,Biochemical and Biophysical Reasearch Communications, 197(3):1126-1131 (1993).
Greene & Wuts, “Protecting Groups in Organic Synthesis”, 3rd edition, 529-580 John Wiley & Sons, New York (1999).
Burnouf et al., “Synthesis, Structure-Activity Relationships, and Pharmacological Profile of 9-Amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6,7,1-hi]indoles: Discovery of Potent, Selective Phosphodiesterase Type 4 Inhibitors”,Journal of Medicinal Chemistry, 43:4850-4867 (2000). •.
Fihi et al., “Reaction of methylene-.gamma.-butyrolactones with arly nitrile oxides. Unexpected bisadduct from 5-methylene-5H-furan-2-one”,Bulletin des Societes Chimiques Beiges, 104(1):55-62 (1995) [Abstract].
Tian et al., “1,3-Dipolar Cycloaddition Reactions of Nitrile Oxides to Prop-1-ene-1,3- sultone”Journal of Heterocyclic Chemistry, 40(6):1071-1074 (2003).
Salgado-Zamora et al., “Oxidative degradation of arylfuro-1,2-oxazoles to arylnitriles by potassium permanganate”Heterocyclic Communications House, 7(3):209-212 (2001).
Hassikou et al., “Synthèse de nouveaux polyhétérocycles”Tetrahedron Letters, 42(34):5857-5861 (2001).
Syassi et al., “Nouvelle méthode de synthèse des 4,5-dihydroisoxazoles en milieu biphasique solide-liquide et par activation ultrasonique”Tetrahedron Letters, 40(40):7250-7209 (1999).
Subramanian et al., “Facile Synthesis of 3-Aroyl-3-Sulfolenes Through Cycloadditions of Arylnitrile Oxides & 3-Sulfolene”Synthetic Communications, 27(15):2557-2562 (1997).
Brahmeshwari et al., “Synthesis of 3-arylnaphth[2,3-d]-isoxazole-4, 9-diones from Lawsone”Indian Journal of Chemistry, Section B, 34B(2):139-140 (1995).
Gaboury and Sibi, “Enantiocontrolled Synthesis of Burseran, Brassilignan, Dehydroxycubebin, and Other Tetrahydrofuran Lignans in Both Enantiomeric Forms. Application of Intermolecular Nitrile Oxide Cycloadditions and Lipase Mediated Kinetic Resolutions”Journal of Organic Chemistry, 58(8):2173-2180 (1993).
Brahmeshwari et al., “Synthesis and biological acivity o
Balachandran Sarala
Dastidar Sunanda G.
Gupta Nidhi
Kukreja Gagan
Palle Venkata P.
Chu Yong
Ranbaxy Laboratories Limited
LandOfFree
Inhibitors of phosphodiesterase type-IV does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of phosphodiesterase type-IV, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of phosphodiesterase type-IV will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4149984